This database contains 9 studies, archived under the term: "postmenopause"
Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens
Wroolie, Tonita E.,
Kenna, Heather A.,
Williams, Katherine E.,
Powers, Bevin N.,
Holcomb, Megan,
Khaylis, Anna,
Rasgon, Natalie L.
Objective: Much controversy exists and many questions remain unanswered about the effects of hormone therapy (HT) on cognition in postmenopausal women. There is growing evidence suggesting that HT compounds containing conjugated equine estrogen (CEE) have negative effects on cognition whereas 17β-estradiol (17β-E) either has positive or neutral effects. The present study sought to further examine […]
Hormone levels and cognitive function in postmenopausal midlife women
Ryan, Joanne,
Stanczyk, Frank Z.,
Dennerstein, Lorraine,
Mack, Wendy J.,
Clark, Margaret S.,
Szoeke, Cassandra,
Kildea, Daniel,
Henderson, Victor W.
Gonadal hormones may influence cognitive function. Postmenopausal midlife women in the population-based Melbourne Women’s Midlife Health Project cohort were administered a comprehensive battery of neuropsychological tests on two occasions 2 years apart. Participants (n = 148, mean age 60 years) had undergone natural menopause and were not using hormone therapy. Estrone, total and free estradiol, […]
Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD
Silverman, Daniel H. S.,
Geist, Cheri L.,
Kenna, Heather A.,
Williams, Katherine,
Wroolie, Tonita,
Powers, Bevin,
Brooks, John,
Rasgon, Natalie L.
Differential cerebral metabolic effects of various hormone therapy formulations, and their associations with cognitive status, remain to be established. The principal aim of the current study was to assess relationships between regional cerebral metabolism and estrogen-based hormone therapies. Postmenopausal women (n=53) at elevated risk for Alzheimer’s disease (AD) were on estrogen-containing hormone therapy for at […]
Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition
Espeland, Mark A.,
Shumaker, Sally A.,
Limacher, Marian,
Rapp, Stephen R.,
Bevers, Therese B.,
Barad, David H.,
Coker, Laura H.,
Gaussoin, Sarah A.,
Stefanick, Marcia L.,
Lane, Dorothy S.,
Maki, Pauline M.,
Resnick, Susan M.
Objective: To compare the relative effects of conjugated equine estrogens (CEE), raloxifene, and tamoxifen therapies on cognition among women aged > or =65 years.; Methods: Annual Modified Mini-Mental State (3MS) examinations were used to assess global cognitive function in the two randomized placebo-controlled clinical trials of CEE therapies of the Women’s Health Initiative Memory Study […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women
Tierney, Mary C.,
Oh, Paul,
Moineddin, Rahim,
Greenblatt, Ellen M.,
Snow, W. Gary,
Fisher, Rory H.,
Iazzetta, John,
Hyslop, Peter St George,
MacLusky, Neil J.
We examined whether estradiol and norethindrone hormone therapy (HT) prevented decline in delayed verbal recall in older women with normal to mildly impaired memory functioning. This was a 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61-87, randomly assigned to receive 1 mg 17-beta estradiol daily and 0.35 mg norethindrone 3 days/week or daily […]
Insulin resistance and medial prefrontal gyrus metabolism in women receiving hormone therapy
Rasgon, Natalie L.,
Kenna, Heather A.,
Wroolie, Tonita E.,
Williams, Katherine E.,
DeMuth, Bevin N.,
Silverman, Daniel H. S.
Insulin resistance (IR) is a putative risk factor for cognitive decline and dementia, and has been shown to impede neuronal glucose metabolism in animal models. This post hoc study focused on metabolic changes in the medial prefrontal region, a brain region exhibiting decline years before documented cognitive changes, relative to high or low IR status […]
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials
Manson, JoAnn E.,
Chlebowski, Rowan T.,
Stefanick, Marcia L.,
Aragaki, Aaron K.,
Rossouw, Jacques E.,
Prentice, Ross L.,
Anderson, Garnet,
Howard, Barbara V.,
Thomson, Cynthia A.,
LaCroix, Andrea Z.,
Wactawski-Wende, Jean,
Jackson, Rebecca D.,
Limacher, Marian,
Margolis, Karen L.,
Wassertheil-Smoller, Sylvia,
Beresford, Shirley A.,
Cauley, Jane A.,
Eaton, Charles B.,
Gass, Margery,
Hsia, Judith,
Johnson, Karen C.,
Kooperberg, Charles,
Kuller, Lewis H.,
Lewis, Cora E.,
Liu, Simin,
Martin, Lisa W.,
Ockene, Judith K.,
O’Sullivan, Mary Jo,
Powell, Lynda H.,
Simon, Michael S.,
Van Horn, Linda,
Vitolins, Mara Z.,
Wallace, Robert B.
Importance: Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.; Objective: To report a comprehensive, integrated overview of findings from the 2 Women’s Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.; Design, Setting, and Participants: A total of 27,347 postmenopausal women aged 50 […]
Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use
Jacobs, Emily G.,
Kroenke, Candyce,
Lin, Jue,
Epel, Elissa S.,
Kenna, Heather A.,
Blackburn, Elizabeth H.,
Rasgon, Natalie L.
Apolipoprotein-ε4 (APOE-ε4) is a major genetic risk factor for cognitive decline, Alzheimer’s disease (AD) and early mortality. An accelerated rate of biological aging could contribute to this increased risk. Here, we determined whether APOE-ε4 status impacts leukocyte telomere length (TL) and the rate of cellular senescence in healthy mid-life women and, further, whether hormone replacement […]